Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...

Gilead Sciences Inc. said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a ...

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...